Patent · US Active

Immunogenic construct comprising an EBV-cell antigen and a targeting moiety and applications thereof

US11147868B2 · kind B2 · utility

0Cited by

0References

16Claims

0Family size

Assignees

Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
UNIVERSITÉ PARIS CITÉ · FR
Institut National Transfusion Sanguine · FR

Inventors

Arnaud Chene · Paris, FR
Benoit Gamain · Washington, US
Stéphane Gangnard · Paris, FR

Key dates

Filing date	Dec 15, 2016
Grant date	Oct 19, 2021
Priority date	—
Expiry date	Dec 15, 2036

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention generally relates to an immunogenic construct, useful for redirecting an EBV-existing immune response towards an undesired target cell and/or microorganism, to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.